Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings

Data ReadoutZ-BasivarsenPositive

AI Analysis

Summary

Dyne Therapeutics will present one-year clinical data from its Phase 1/2 ACHIEVE trial of Z-Basivarsen (DYNE-101) for myotonic dystrophy type 1 at upcoming medical meetings, including comparisons to a matched natural history cohort.

Clinical Trial Data

Phase

1/2

Outcome Details

One-year clinical data from Phase 1/2 ACHIEVE trial to be presented at upcoming medical meetings

Importance:5/10

Sentiment:

0.30

Phase 1/2myotonic dystrophyantisense therapyclinical data presentationrare disease

Related Companies

$MDCE $NAII $ACHV

Read the original article

Published by GlobeNewswire Clinical Studies on September 8, 2026 11:51 AM

Read Original